Day: June 13, 2025

PRESS RELEASE Arcueil, June 13, 2025 2025 half-year financial report release Aramis Group today announces that the company has filed its 2025 half-year financial report, ended March 31, 2025, with the French Financial Markets Authority (Autorité des marchés financiers). Aramis Group 2025 half-year financial report is available on the Company’s website www.aramis.group under “Investors / Regulated information”. *** About Aramis Group – www.aramis.group Aramis Group is the European leader for B2C online used car sales and operates in six countries. A fast-growing group, an e-commerce expert and a vehicle refurbishing pioneer, Aramis Group takes action each day for more sustainable mobility with an offering that is part of the circular economy. Founded in 2001, it has been revolutionizing its market for over 20 years, focused on ensuring...

Reference is made to announcements from Kvika banki hf. (“Kvika” or “the Bank”) dated 27 and 28 May, stating that Arion banki hf. and Íslandsbanki hf. had each expressed interest in initiating merger discussions with Kvika. Following due consideration, the Board of Kvika has concluded that the proposals received from Arion banki hf. and Íslandsbanki hf. on 27 and 28 May do not reflect the intrinsic value of Kvika. The Board therefore does not believe that entering into merger discussion based on these proposals is in the best interest of the bank. Nonetheless, the Board of Kvika is of the opinion that significant opportunities and value could be realised through a potential combination of businesses, to the benefit of both shareholders and customers. Should the interested parties be willing to improve their proposals, the Board is open...

               PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development StrategyPolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA. The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG’s Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1).Gdańsk, Poland – 13 JUNE 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, announces that it has established a wholly owned subsidiary, Immuthera, a United States C Corporation, in the state of Delaware. This is a further step by PolTREG to deepen its entry into the U.S. market. “Over...

Siili Solutions Plc       Announcement  13.6.2025                Siili Solutions Plc: Share Repurchase 13.6.2025           In the Helsinki Stock Exchange             Trade date           13.6.2025    Bourse trade         Buy    Share                  SIILI    Amount             1 100 Shares  Average price/ share    6,2091 EUR  Total cost            6 830,01 EUR                Siili Solutions Plc now holds a total of 11 398 shares  including the shares repurchased on 13.6.2025           The share buybacks are executed in compliance with Regulation   No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.         On behalf of Siili Solutions Plc             Nordea Bank Oyj             Sami...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women’s Hospital, and the University of Massachusetts. The Phase 2 trial aims to evaluate the safety and efficacy of Tiziana’s innovative therapies in treating...

The acquisition by Heimar hf. (“Heimar” or the “Company”) of all shares in Gróska ehf. (“Gróska”) and Gróðurhúsið ehf. (“Gróðurhúsið”) (the “Transaction”), which was initially announced on 23 April this year, has now been completed.  Gróska owns the property Gróska, located at Bjargargata 1, 102 Reykjavík, an innovation hub and one of Iceland’s largest and most ambitious office buildings. The property comprises approximately 18,600 square meters of floor area and a 6,200 square meter underground car park with 205 spaces, totaling approximately 24,800 square meters. Gróðurhúsið operates a startup incubator and coworking spaces within the premises. The property is BREEAM certified, and as a result of the acquisition, the proportion of Heimar’s certified assets has increased from 38.9% to 41.1%.  Tenants at Gróska...

Le Mans Ultimate to Launch Full 1.0 Release on July 22, 2025, Introducing Mercedes AMG LMGT3 Evo, Aston Martin Valkyrie, and a Glimpse Into the FutureLe Mans Ultimate is set to be full released on 22nd July 2025, including the Aston Martin Valkyrie AMR and the Mercedes AMG LMGT3 Evo. Additionally, the European Le Mans Series content is confirmed for the title as well as future plans for a career mode.MIAMI, June 13, 2025 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) today revealed the next major chapter for Le Mans Ultimate, announcing the game’s official 1.0 release date for July 22, 2025. This milestone marks the conclusion of the title’s Early Access period and the beginning of a new phase in its development—one driven by community feedback, technical growth, and an unrelenting...

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 – SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody,...

PALO ALTO, CA, June 13, 2025 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”) a recognized leader in AI surveillance and remote guarding solutions, today announced that a leading national property management firm, with assets across 18 states, has selected the Company’s advanced AI Surveillance platform to enhance security at a prominent mixed-use community. The decision aims to address persistent security challenges affecting both residents and retail tenants. The property—a large-scale development that blends residential, retail, and commercial spaces—has faced escalating security challenges, including frequent vehicle break-ins, unauthorized access through retail entrances, and the traumatic experience of an active shooter in the vicinity. Seeking a comprehensive,...

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™ mesh, CGuard is designed to reduce both early and late embolic events by trapping debris against the vessel wall, preventing plaque prolapse and embolization that can cause stroke. “Securing CE Mark certification under the EU MDR is a major milestone that demonstrates InspireMD’s commitment to advancing our next-generation platforms, regulatory rigor, and execution,” said...